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Abstract 68 
Adenosine as well as agonists and antagonists for the four adenosine receptor subtypes (A1R, A2AR, 69 
A2BR and A3R) play a role in several key physiological and pathophysiological processes, including 70 
the regulation of vascular tone, thrombosis, immune response, inflammation, and angiogenesis. This 71 
review focuses on the adenosine-mediated regulation of lipid availability in the cell and in the systemic 72 
circulation as well in humans and animal models. Therefore, adenosine, mainly by acting on A1R, 73 
inhibits lipolysis activity, leading to reduction of the circulating fatty acid levels. This nucleoside can 74 
also participate in the early development of atherosclerosis by inhibiting the formation of foam cells via 75 
stimulation of cholesterol efflux through A2AR expressed on macrophages and reduction of the 76 
inflammatory process by activating A2AR and A2BR. Adenosine also appears to modulate intracellular 77 
cholesterol availability in Niemann-Pick type C1 disease and Alzheimer disease via A2AR and A3, 78 
respectively. Remarkably, the role of adenosine receptors in the regulation of plasma total cholesterol 79 
and triglyceride levels has been studied in animal models. Thus, an anti-atherogenic role for A2BR as 80 
well as a pro-atherogenic role of A2AR and A1 have been proposed; A3R has not been shown to 81 
participate in the control of lipid levels or the development of atherosclerosis. Surprisingly, and despite 82 
the role of A2A in the inhibition of foam cell formation among isolated cells, this receptor appears to be 83 
pro-atherogenic in mice. Remarkably, the role of adenosine receptors in human dyslipidaemia and 84 
atherosclerosis must to be elucidated. Additionally, it has been reported that increased lipid levels impair 85 
the effects of adenosine/adenosine receptors in controlling vascular tone, and we speculate on the 86 
possibility that this impairment could be due to alterations in the composition of the membrane 87 
microdomains where the adenosine receptors are located. Finally, a possible role for 88 
adenosine/adenosine receptors in the phenomena of dyslipidaemia in pregnancy has been proposed. 89 
 90 
Keywords: adenosine; cholesterol; triglycerides; atherosclerosis; pregnancy 91 
 92 
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1. Introduction 95 
Adenosine is a nucleoside that has been implicated in a wide variety of biological functions, including 96 
the regulation of lipid (e.g., cholesterol, triglycerides and fatty acids) availability in the cell (Reiss et al., 97 
2012) and in the systemic circulation (Koupenova et al., 2012a). The effects of adenosine are mediated 98 
by the action of this nucleoside on four different adenosine receptors (ARs). Interestingly, the adenosine 99 
levels in the extracellular space are also modulated by the synthesis and transport of the nucleoside into 100 
the cell (Karmouty-Quintana et al., 2013). Based in the role of adenosine in the regulation of lipid 101 
availability, this molecule, as well as specific agonists and antagonists that can increase or inhibit AR 102 
function, respectively, have been proposed as therapeutic agents for classical diseases related to 103 
disturbed lipid levels, such as diabetes and atherosclerosis, and diseases that involve the nervous system, 104 
such as Niemann-Pick type C1 and Alzheimer disease. This article reviews the evidence showing the 105 
mechanism of adenosine/AR modulation of lipid levels. We also propose a possible regulatory 106 
mechanism of ARs on the increased levels of circulating lipids. Finally, we propose a possible role for 107 
adenosine/ARs in the development of maternal dyslipidaemia during pregnancy. 108 
 109 
2. Adenosine synthesis and signalling 110 
Adenosine is a purine nucleoside with a wide variety of basic functions in the vascular, nervous, 111 
respiratory, endocrine and reproductive systems that are mediated by the activation of ARs localized to 112 
the extracellular surface of the cell membrane (Ralevic and Dunn, 2015). Adenosine participates in the 113 
regulation of the immune response (Di Virgilio and Vuerich, 2015), angiogenesis (Auchampach, 2007), 114 
thrombosis (Fuentes et al., 2014), lipolysis (Peng et al., 2009; Schwabe et al., 1974), plasma lipid levels 115 
(Koupenova et al., 2012b), vasodilatation; additionally, it has been shown to affect the cardiovascular 116 
system (Eisenstein et al., 2015), the placenta (Sobrevia et al., 2015) and cholesterol efflux and 117 
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inflammation, the latter two of which are involved in the development of atherosclerosis (Reiss et al., 118 
2012). 119 
 120 
2.1 Adenosine synthesis 121 
Extracellular and intracellular adenosine synthesis as well as the function of nucleoside membrane 122 
transporters are key biological processes that modulate the extracellular availability of adenosine as well 123 
as the function and signalling of ARs.  124 
Extracellular adenosine synthesis begins with the phospho-ester hydrolysis of its precursor molecule 125 
ADP or ATP, which is released by tissues (e.g., brain) (Bekar et al., 2008), electrically stimulated sensor 126 
cells (Yamashiro et al., 2017), extracellular vesicles, platelet vesicles (Weissmüller et al., 2008) and 127 
platelets in the blood (Kohli et al., 2016). ATP is rapidly converted to ADP and AMP via the enzyme 128 
ecto-nucleoside triphosphate diphosphohydrolase 1 (CD39) (Grenz et al., 2007; Köhler et al., 2007) and 129 
is further metabolized to form adenosine via ecto-5-nucleotidase (CD73) (Fredholm et al., 2007). CD39 130 
and CD73 are extracellular membrane enzymes (Caldwell et al., 1997) that regulate the availability of 131 
adenosine (Figure 1) (Robson et al., 2005). After adenosine uptake by adenosine transporters (see 132 
below), adenosine is either rapidly metabolized to inosine by the enzyme adenosine deaminase (ADA) 133 
(Colgan et al., 2006; Lloyd and Fredholm, 1995) or converted to AMP by the enzyme adenosine kinase 134 
(Figure 1) (Eltzschig, 2009; Fredholm et al., 2007). The extracellular levels of adenosine are also 135 
influenced by extracellular ecto-adenosine deaminase (ecto-ADA, that metabolize adenosine to inosine), 136 
which is physiologically relevant because its activity regulates AR function (Karmouty-Quintana et al., 137 
2013; Pacheco et al., 2005). Indeed, increased ecto-ADA activity is considered a marker of 138 
inflammation (Vinapamula et al., 2015) and atherosclerosis (Kutryb-Zajac et al., 2016). 139 
The intracellular production of adenosine corresponds to the metabolism of intracellular ATP, ADP, and 140 
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AMP via the action of cytoplasmic 5’-nucleotidases. Additionally, adenosine can be synthetized by 141 
hydrolysing S-adenosyl-homocysteine via the enzyme S-adenosylhomocysteine hydrolase (Samsel and 142 
Dzierzbicka, 2011). Adenosine is then released into the extracellular environment by nucleoside 143 
membrane transporters (Figure 1). 144 
2.2 Adenosine transport 145 
The activation of ARs depends on the extracellular adenosine levels; thus, adenosine transport plays an 146 
essential role in the function of the receptors (Pardo et al., 2013). Pharmacological studies using 147 
adenosine transporter inhibitors have revealed the relevance of the adenosine transport in health and 148 
disease. 149 
Extracellular adenosine is uptaken via nucleoside transporters, which have been stratified into two 150 
families: equilibrative nucleoside transporters (ENTs, SLC29), which are characterized by facilitated 151 
diffusion and sodium-independent transport of nucleosides and nucleobases; and concentrative 152 
nucleoside transporters (CNTs, SCL28), a sodium-dependent transport system (Figure 1) (Yang and 153 
Leung, 2015).  154 
The ENT family is formed by four members termed ENT 1 to 4. All of them transport adenosine but 155 
differ in their capacity to transport other nucleosides or nucleobases (Yang et al., 2008). ENT1 and 156 
ENT2 are ubiquitously localized broad-selectivity ENTs that have been classified based on their 157 
sensitivity to inhibition by nitrobenzylthioinosine (NBTI) as either “es” (i.e., equilibrative-sensitive, Ki 158 
< 1 µM, ENT1) or “ei” (i.e., equilibrative-insensitive, Ki > 1 µM, ENT2) (Löffler et al., 2007; Young et 159 
al., 2008). ENT3 and ENT4 have also been classified as “es”, but ENT3 is expressed in the placenta, 160 
liver, and tumour tissues (Baldwin et al., 2004; Hyde et al., 2001), and ENT4 is ubiquitously expressed 161 
and has pH-dependent activity (Baldwin et al., 2004; Barnes et al., 2006). 162 
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The CNT family is characterized by active sodium-dependent transport and contains three members 163 
termed CNT 1 to 3, all of which have been cloned. These transporters differ in their substrate selectivity: 164 
CNT1 transports pyrimidine nucleosides and adenosine (cif, concentrative system, insensitive to NBTI, 165 
formicin B inhibitor), CNT2 transports purine nucleosides and uridine (cit, concentrative system, 166 
insensitive to NBTI, a thymidine inhibitor), and CNT3 transports both pyrimidine and purine 167 
nucleosides (cib, concentrative system, insensitive to NBTI, a tubercidine inhibitor) (Löffler et al., 2007; 168 
Pastor-Anglada et al., 2008; Podgorska et al., 2005). CNTs are expressed in several cell types, including 169 
renal proximal tubule cells (Elwi et al., 2009), hepatocytes (Govindarajan et al., 2008), colonic cells 170 
(e.g., HT-29 cells) (Fernández-Calotti et al., 2016), human syncytiotrophoblasts (Errasti-Murugarren et 171 
al., 2011), endothelial cells (Parkinson et al., 2011) and endothelial progenitor cells (Guzmán-Gutiérrez 172 
et al., 2010).  173 
 174 
2.3 Adenosine receptors 175 
Extracellular adenosine serves as a signalling molecule by activating one of four Ars denoted as the A1 176 
receptor (A1R), A2A receptor (A2AR), A2B receptor (A2BR) and A3 receptor (A3R) (Figure 1). Ars 177 
compose the P1 purinergic receptor family and are G-protein coupled receptors (Burnstock et al., 2011; 178 
Fredholm et al., 2011). Regarding the structure of the receptors; they have a short (7-13 residues) N-179 
terminal domain, a C-terminal domain (32-120 residues) and several transmembrane domains that have 180 
between 39-61% sequence identity among the different Ars (Burnstock, 2006). All four Ars co-exist in 181 
most tissues; however, different tissues usually have a dominant receptor subtype with the other 182 
subtypes playing a modulatory or a compensatory role. Thus, the different biological functions of 183 
adenosine depend of the expression pattern of Ars on individual cell types or in a specific tissue 184 
(Feoktistov et al., 2002; Liu and Hofmann, 2002; Wyatt et al., 2002). Changes in the expression pattern 185 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
8 
of Ars under pathophysiological conditions such as hypoxia, ischaemia or inflammation have the 186 
potential to significantly alter AR signalling events (Karmouty-Quintana et al., 2013). 187 
A1R, A2AR and A3R are activated at nanomolar concentrations of adenosine, while A2BR requires 188 
micromolar concentrations (Fredholm et al., 2011). A1R and A3R are recognized as inhibitory receptors 189 
coupled to the guanosine 5′-triphosphate (GTP)-binding Gi/Go protein. Conversely, A2AR and A2BR 190 
are recognized as activating receptors coupled to the stimulatory Gs protein (Klinger et al., 2002). 191 
Signalling pathways associated with A1R and A3R include adenyl cyclase inhibition, phospholipase C 192 
(PLC) activation and PI3K/Akt activation; however, A2AR and A2BR induce adenyl cyclase activity 193 
(Eltzschig, 2009; Fredholm et al., 2011). Nevertheless, all Ars stimulate MAPK signalling (Figure 1) 194 
(Eltzschig, 2009; Klinger et al., 2002; Schulte and Fredholm, 2003).  195 
 196 
3. The role of adenosine in regulating lipid availability 197 
3.1 Lipolysis 198 
Lipolysis is the catabolic pathway through which triglycerides are enzymatically hydrolysed to non-199 
esterified fatty acids (NEFAs) and glycerol, a process inhibited by A1R activation (Johansson et al., 200 
2008; MacPherson et al., 2016), which is involved in lipolysis. NEFAs are important metabolic 201 
substrates, and their release from adipose tissue provides an energy source, precursors for lipid and 202 
membrane synthesis and mediators in cell signalling processes (Duncan et al., 2007; MacPherson et al., 203 
2016). Additionally, elevated plasma levels of NEFAs play a significant role in the pathogenesis of 204 
insulin resistance, diabetes, dyslipidaemia and arrhythmia as well as left ventricular dysfunction in the 205 
heart, where NEFAs alter electrical and mechanical activity (Dhalla et al., 2009; Winhofer et al., 2015). 206 
Thus, drugs designed to reduce plasma NEFA levels by reducing lipolysis may represent an effective 207 
therapy for those conditions (Dhalla et al., 2009). 208 
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There are many upstream regulators that either stimulate or inhibit lipolysis by altering the activity of 209 
lipase enzymes. Catecholamines are one of the most well defined pathways that stimulate this process 210 
(Chaves et al., 2011). Moreover, insulin and adenosine are the most important molecules that inhibit 211 
lipolysis, but their mechanisms and activities are different, and the effects are not synergistic (Johansson 212 
et al., 2008; Zhang et al., 2013) 213 
Adenosine is secreted by adipocytes in which the main adenosine receptor is A1R (Johansson et al., 214 
2007; Schoelch et al., 2004). A1R activation leads to reduced cAMP levels that control the lipolytic 215 
process mainly by regulating cAMP-dependent protein kinase and lipases activity (Johansson et al., 216 
2007).  217 
 218 
Early data in animal models and human cells suggested that A1R agonists participate in the inhibition of 219 
lipolysis (Figure 2A) (Fain and Wieser, 1975; Schwabe et al., 1974). Lipolysis, as evaluated by glycerol 220 
release, is normally induced in adipocytes exposed to noradrenaline and is inhibited by the addition of 221 
A1R agonists such as phenylisopropyladenosine (PIA) and GR79236 in adipocytes isolated from 222 
humans, rats and dogs (Hoffman et al., 1984; Strong et al., 1993). Thus, the intravenous infusion of 223 
GR79236 in rats led to a decrease in the plasma NEFA levels (Merkel et al., 1995; Strong et al., 1993). 224 
Lipolysis is potentiated by adenosine removal via ADA or by incubation with the A1R antagonist 225 
DPCPX in rat (Szkudelski et al., 2009) and mouse adipocytes (Johansson et al., 2007). This 226 
phenomenon is reduced after incubation with antilipolytic molecules such as insulin or the adenosine 227 
agonist 2-chloroadenosine (2-CADO) (Johansson et al., 2007, 2008). Interestingly, in adipocytes 228 
isolated from A1R-deficient mice (A1RKO), the described antilipolytic effect of the adenosine analogue 229 
was abolished, suggesting that A1R is required for this process (Johansson et al., 2008). At the systemic 230 
level, the administration of the adenosine analogue N6-cyclopentyladenosine (CPA) in wild-type mice 231 
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was associated with reduced plasma levels of NEFAs, glycerol and triglycerides without changes in the 232 
cholesterol levels (Johansson et al., 2008). The pivotal role of A1R as an inhibitor of lipolysis was also 233 
determined in transgenic mice that overexpress A1R in adipose tissue (Dong et al., 2001). Compared 234 
with wild-type mice, the transgenic mice showed lower NEFA levels, confirming the role of A1R in 235 
lipolysis. 236 
 237 
As in animal models, adenosine also has antilipolytic effects on adipocytes isolated from humans as 238 
shown by the adenosine analogues PIA and GR79236 (Heseltine et al., 1995; Ohisalo, 1981). In these 239 
cells, lipolysis induced by isoproterenol, noradrenaline or ADA-induced adenosine depletion was 240 
inhibited in a dose-dependent manner by A1R analogues (Heseltine et al., 1995; Ohisalo, 1981). As 241 
previously described, A1R agonists appear to be good candidates for the inhibition of lipolysis; 242 
therefore, a possible use of these molecules for the treatment of pathological conditions in which NEFAs 243 
play an important role was proposed (Dhalla et al., 2009). Interestingly, the therapeutic use of A1R 244 
agonists as antilipolytic agents has been assayed in a few studies involving human subjects (Table 1). 245 
However, these agonists have side effects in cells other than adipocytes (e.g., bradycardia in 246 
cardiomyocytes) (Bragança et al., 2016). herefore, drugs designed to decrease the concentration of 247 
these lipids could be considered as possible therapeutic targets (Shao et al., 2014). New agonists for 248 
A1R should to be developed and probed to delineate the beneficial and adverse effects of the antagonists 249 
(Fraser et al., 2003). Therefore, agonists that promote signalling for the cytoprotection to decrease 250 
lipolysis without activating pathways that lead to bradycardia, a phenomenon known as biased agonism 251 
which is defined as the ability of ligands to stabilize different conformations of G protein-coupled 252 
receptors, can result in differential signalling that allows for the design of pathway-specific drugs to 253 
avoid adverse effects (Herenbrink et al., 2016). Thus, it has been described that A1R agonists such as 254 
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ARA, CVT3619, CVT510, VCP746 and capadenoson inhibit lipolysis, resulting in cardio-protection 255 
without cardiovascular side effects (Baltos et al., 2016; Dhalla et al., 2007; Fraser et al., 2013; Shearer et 256 
al., 2009). In humans, ARA lowered the plasma levels of NEFAs when administered intravenously to 10 257 
healthy volunteers in a phase I clinical study. However, this group exhibited a phenomenon of tolerance 258 
to the NEFA-lowering effects of ARA, indicating that desensitization of adenosine receptors occurs and 259 
that a period of abstinence of agonist administration may be required for achieve the antilipolytic effects 260 
(Zannikos et al., 2001). The cellular mechanisms suggested to be involved in this desensitization 261 
phenomenon is related with a reduced number of receptors at the cell surface mediated by receptor 262 
uncoupling from G proteins via activation of the beta-arrestin1/ERK1/2 pathway (Jajoo et al., 2010; 263 
Longabaugh et al., 1989). Another mechanism that could be involved in receptor desensitization is an 264 
enhanced rate of cAMP synthesis and reduced cAMP metabolism, which leads to the accumulation of 265 
intracellular cAMP; this preserves the activity of intracellular kinases to maintain a high rate of lipolysis 266 
despite the presence of an adenosine agonist (Hoffman et al., 1986, 1989). Another agonist assayed in 267 
human patients was GS-9667, a highly selective partial agonist of A1R. Oral administration of this 268 
agonist in 47 non-obese and 41 obese volunteers caused a dose-dependent reduction in NEFA levels in 269 
both patient groups. The results were reproducible over 14 days without evidence of A1R 270 
desensitization or changes in heart rate and blood pressure (Staehr et al., 2013). Because the receptor 271 
density and receptor reserve are higher in adipose tissue than in cardiac tissue, GS-9667 inhibited 272 
lipolysis at concentrations that had minimal or no effect on A1R-mediated reduction of the heart rate.  273 
Finally, all this information strongly demonstrates the essential role of A1R alone in the process of 274 
lipolysis and in the control of plasma NEFA levels, highlighting that drugs designed to decrease the 275 
concentration of these lipids could be considered as possible therapeutic mechanism targeting the 276 
pathologies associated with increased levels of these lipids (Shao et al., 2014). 277 
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 278 
3.2 Foam cell formation  279 
In addition to regulating NEFAs in adipocytes, adenosine and ARs also regulate the content of 280 
cholesterol in monocytes/macrophages by increasing cholesterol efflux via A2AR activation and 281 
reducing inflammation via A2AR and A2BR activation, two process that are directly related with the 282 
formation of foam cell and thus with the development of atherosclerosis (Koupenova et al., 2012b; Reiss 283 
et al., 2012).  284 
Endothelial dysfunction triggered by increases in circulating lipid levels and inflammation is one of the 285 
first pathogenic events for the development of atherosclerosis; these events favour the attachment of 286 
monocytes as well as their entry into the sub-endothelial space and intima layer, where the monocytes 287 
express chemokines to amplify the inflammatory signal (Libby et al., 2002; Mestas and Ley, 2008). At 288 
this point, monocytes change their phenotype to become macrophages that express scavenger receptors 289 
to uptake oxidized LDL (Kunjathoor et al., 2002; Moore and Tabas, 2011). Lipid accumulation in the 290 
macrophage cytoplasm drives its conversion into a foam cell, which released reactive oxygen species, 291 
pro-inflammatory cytokines and metalloproteinases. The accumulation of foam cells in the intima space 292 
leads to the development of a fatty streak or early atheromatous lesion (Figure 3) (Libby et al., 2002; 293 
Virmani et al., 2002). Therefore, regulating the lipid content in macrophages is a physiological process 294 
that can prevent atherogenic progression.  295 
In this context, the cholesterol efflux process is responsible for removing excess cholesterol from 296 
macrophages to prevent foam cell formation. The main proteins involved in the cholesterol efflux 297 
process are adenosine 5-tri-phosphate-binding cassette transporter A1 and G1 (ABCA1, ABCG1) and 298 
cholesterol 27-hydroxylase (CYP27A1) (Reiss et al., 2004). ABCA1 and ABCG1 bind to apolipoprotein 299 
AI (ApoA1, the main protein of the HDLs) and HDLs, respectively, and deliver cholesterol and 300 
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phospholipid content from macrophages to circulating lipoproteins (Oram et al., 2000). CYP27A1 is an 301 
enzyme involved in the conversion of cholesterol to oxysterol and in the efflux of cholesterol to ApoA1 302 
because oxysterols activate ABCA1 transcription, resulting in increased cholesterol efflux (Escher et al., 303 
2003). 304 
 305 
3.2.1 Cholesterol efflux 306 
The stimulation of this process by ARs has been studied mostly in macrophage cell culture, where the 307 
main AR involved is A2AR and there is no information regarding the participation of the other ARs 308 
(Voloshyna et al., 2013a) (Figure 2B). The selective A2AR agonist CGS 21680 inhibited foam cell 309 
formation in human (THP-1 cells) and murine peritoneal macrophages exposed to the pro-inflammatory 310 
cytokines IL-1β and TNF-α (Reiss et al., 2004). This inhibition was absent in macrophages collected 311 
from A2AR-deficient mice (A2AR KO), suggesting an anti-atherogenic role for A2AR at least in 312 
cultured macrophages. Additionally, inhibition of A2AR function with either the antagonist ZM241385 313 
or small interfering RNAs targeting A2AR was associated with lipid accumulation in human 314 
macrophages and aortic endothelial cells as well as enhanced foam cell formation (Voloshyna et al., 315 
2013a). This study confirmed the role of A2AR in foam cell formation in cultured cells (Figure 2B). 316 
Since foam cell formation is associated with down-regulation of the proteins responsible for cholesterol 317 
efflux (ABCA1, ABCG1 and CYP27A1), the influence of A2AR on the expression of these proteins 318 
was determined. Activation of A2AR by CGS 21680 or ATL313 increased the expression of ABCA1, 319 
ABCG1 and CYP27A1 in human macrophages (Reiss et al., 2004, 2012; Voloshyna et al., 2013a). To 320 
determine the role of these proteins in cholesterol efflux and foam cell formation after A2AR activation 321 
with CGS 21680, their expression levels were reduced in cultured macrophages using lentiviral siRNA 322 
for targeting ABCA1, ABCG1 (Bingham et al., 2010) or CYP27A1 (Bingham et al., 2012). When 323 
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ABCG1 expression was decreased, the A2AR agonist prevented foam cell formation by increasing 324 
cholesterol efflux, an effect that was absent in cells with ABCA1 knockdown, demonstrating that the 325 
ABCA1 transporter mediates the A2AR-dependent increase in cholesterol efflux in isolated 326 
macrophages (Bingham et al., 2010). Additionally, in cells with CYP27A1 knockdown (enzyme that 327 
regulate ABCA1 expression), the effects of CGS 21680 on cholesterol efflux were absent, suggesting 328 
that the A2A agonist prevents foam cell formation by increasing the expression and function of 329 
CYP27A1(Bingham et al., 2012). 330 
Interestingly, the activation of exchange protein directly activated by cAMP (EPAC), a downstream 331 
signalling molecule of A2AR, increased ABCA1 expression and function, suggesting that A2AR can 332 
stimulate proteins involved in cholesterol efflux in a different manner (Bingham et al., 2010; Reiss et al., 333 
2012).  334 
Additionally, in affecting cholesterol efflux, the cellular uptake of oxidized LDL was decreased in 335 
human macrophages treated with the A2AR agonist ATL313, suggesting that in cultured macrophages, 336 
this receptor can also inhibit foam cell formation by reducing cholesterol uptake (Voloshyna et al., 337 
2013a).  338 
 339 
In the context of treating atherosclerotic coronary heart disease, the anti-inflammatory polyphenol 340 
resveratrol is a molecule with atheroprotective activity (Bonnefont-Rousselot, 2016). In macrophages, 341 
resveratrol increases the expression of proteins involved in cholesterol trafficking, including LDL and 342 
HDL receptors (Xin, et al., 2013); the cholesterol transporters ABCA1, ABCG1 and CYP27A1 (Sevov 343 
et al., 2006; Voloshyna et al., 2013b) and the cholesterol acceptors ApoAI and HDL (Berrougui et al., 344 
2009), thereby reducing foam cell formation (Park et al., 2009). Interestingly, resveratrol is also 345 
associated with increased levels of adenosine in human blood (Blardi et al., 1998), and data indicated 346 
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that the effect of polyphenols on the previously described molecules and subsequently on foam cell 347 
formation is mediated by A2AR activation since this activity was completely abolished in human 348 
macrophages and aortic endothelial cells exposed to the A2AR antagonist ZM-241385 (Voloshyna et al., 349 
2013b).  350 
Finally, evidence supports the hypothesis that activation of A2AR by adenosine is involved in 351 
cholesterol efflux to reduce foam cell formation in isolated macrophages. Therefore, it has been 352 
proposed that adenosine/A2AR could play a role as an atheroprotective molecule (Figure 3C). 353 
Remarkably, all these studies were developed in isolated macrophages and not in a full organ/animal 354 
system where this receptor could exert additional functions in other cells. 355 
 356 
3.2.2 Inflammation  357 
Inflammation, a process inhibited by adenosine (mainly by action on A2AR and A2BR), is an essential 358 
factor in promoting foam cell formation and atherosclerosis (Eisenstein et al., 2015) (Figure 2B).  359 
The role of A2AR in regulating the inflammatory state has been described in human cells and in mice. 360 
In human monocytes, stimulation with the pro-inflammatory cytokines IL-1β (Khoa et al., 2001) and 361 
TNF-α (Khoa et al., 2001; Kreckler et al., 2006) triggered the modulation of A2AR leading to increased 362 
levels of cAMP and the secretion of the anti-inflammatory cytokines IL-10 and IL-12, thereby 363 
decreasing the inflammatory response (Khoa et al., 2001). In a murine model of inflammation induced 364 
by carotid ligation, the expression levels of the adhesion molecules VCAM-1, ICAM-1, and P-selectin 365 
as well as the neointimal area of the aorta are induced (Kumar et al., 1997). Interestingly, the infusion of 366 
the A2AR agonist ATL-146e in this mouse model was associated with decreased expression of the 367 
adhesion molecules, an 80% reduction of the neointimal area and decreased macrophages and 368 
leukocytes content than in model mice administered no agonist treatment, an infusion of the selective 369 
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A2AR antagonist ZM241385, or co-treatment of ATL-146e and ZM24138, suggesting that the effects of 370 
ATL-146e were specifically mediated by A2AR (McPherson et al., 2001).  371 
The anti-inflammatory role of A2BR was shown in murine bone marrow-derived macrophages. In this 372 
model, the activation of all the ARs with the nonselective agonist NECA but not with specific agonists 373 
for A1R (R-PIA), A2AR (CGS 21680) or A3R (IB-MECA) was associated with inhibited TNF-α 374 
(Kreckler et al., 2006; Xaus et al., 1999) and IL-1β (Xaus et al., 1999) production as well as an increase 375 
in IL-10 production (Németh et al., 2005). More evidence has linked A2BR with anti-inflammation, 376 
suggesting that preserving or overexpressing A2BR in macrophages could reverse (Cohen et al., 2015) 377 
or deactivate (Xaus et al., 1999) the inflammatory phenotype of macrophages. Remarkably, an A2BR-378 
deficient mouse model presented increased levels of inflammatory markers such as TNF-α and IL-6 and 379 
reduced levels of the anti-inflammatory marker IL-10 either at basal conditions or after LPS stimulation 380 
versus control mice (Yang et al., 2006). In the same A2BR-deficient mice, profound alterations in 381 
glucose and lipid metabolism together with increased levels of inflammatory markers, including TNF-α 382 
and IL-6, and decreased levels of IL-10, were observed (Csóka et al., 2014). In the RAW 264.7 383 
macrophage cell line, the activation of ARs with the nonselective adenosine receptor agonist NECA 384 
diminished the inflammatory activation induced by free fatty acids. This phenomenon was not observed 385 
after incubation with agonists for A1R, A2AR or A3R (CCPA, CGS 21680 and 2-Cl-IB-MECA, 386 
respectively) and was abolished in cells treated with the A2BR antagonist PSB0788, therefore 387 
supporting the anti-inflammatory role of A2BR (Csóka et al., 2014). Despite these data, it has been 388 
suggested that A2BR could mediate a secondary inhibitory action since the A2BR antagonist MRS1754 389 
could block the ability of NECA to inhibit TNF-α release from macrophages isolated from A2AR-390 
deficient mice; however, this effect is absent in macrophages isolated from wild-type mice. These results 391 
suggest that A2AR is more efficient in this role than A2BR (Kreckler et al., 2006). Additionally, 392 
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regarding the role of A2AR and A2BR in inhibiting the pro-inflammatory cytokine response, it has been 393 
proposed that there is also a complementary role of A3R. The role of A3R is controversial because it has 394 
been suggested that A3R is capable of suppressing TNF-α expression (Haskó et al., 2000; Haskó and 395 
Cronstein, 2004), and the use of the A3AR agonist IB-MECA potently inhibited TNF-α release from 396 
macrophages collected from A2AR knockout mice (A2AR KO). However, when activated wild-type 397 
monocytes and an A3AR agonist were used, no effect was found on cytokine production (Kreckler et al., 398 
2006), suggesting that A3R can play a potential role in the absence of A2AR.  399 
Finally, all this evidence suggests that ARs, mainly A2AR and A2BR, participate in cellular cholesterol 400 
homeostasis to regulate foam cell formation and that inflammation prevents the adverse effects that 401 
these processes can trigger (Figure 3D). In particular, A2AR and A2BR are potentially relevant for the 402 
atherogenic processes; therefore, these receptors could be considered as a therapeutic tool for preventing 403 
atherosclerotic cardiovascular disease. 404 
 405 
3.3 Intracellular cholesterol trafficking 406 
As previously described, Ars expressed on macrophages participate in cellular cholesterol homeostasis 407 
by regulating cholesterol efflux in these cells. Remarkably, it has been shown that ARs also regulate 408 
cellular cholesterol homeostasis by modulating intracellular cholesterol trafficking. Niemann-Pick type 409 
C1 (NPC1) is a membrane protein expressed on endosomes and lysosomes that mediates intracellular 410 
cholesterol trafficking. This protein transports LDL to late endosomal/lysosomal compartments where 411 
the lipoprotein is hydrolysed, and free cholesterol is released. Loss-of-function mutations of the NPC1 412 
gene cause Niemann-Pick type C1 disease, a pathology characterized by abnormal intracellular 413 
cholesterol trafficking that is associated with intracellular (i.e., lysosomal) accumulation of unesterified 414 
cholesterol (Chang et al., 2005) and alterations in calcium homeostasis (Lloyd-Evans et al., 2008). This 415 
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aberrant activity in the lysosomal compartment together with impaired normal mitochondrial function 416 
(Yu et al., 2005) often manifests in hepatic and neuronal cells. This dysregulation can result in 417 
hepatosplenomegaly, neurological damage and death at an early age (Chang et al., 2005). Currently, this 418 
disease still does not have cure and the available treatments are insufficient. In this context, it has been 419 
shown that the A2AR agonist CGS 21680 produces a significant decrease of intracellular cholesterol 420 
accumulation as well as increased lysosomal calcium and subsequent mitochondrial function in a 421 
fibroblast cell line derived from NPC1 patients. The beneficial effects of A2AR agonists were blocked 422 
by the A2AR antagonist ZM241385, suggesting that this activity is dependent on the activation of 423 
A2AR (Visentin et al., 2013). Additionally, it has been shown that the use of CGS 21680 in NPC1 424 
human neuroblastoma and oligodendroglia cell lines with reduced NPC1 protein expression led to 425 
decreased intracellular cholesterol accumulation and improved mitochondrial function (Ferrante et al., 426 
2016). In a similar manner as in fibroblasts from NPC1 patients, the beneficial effects of A2AR agonists 427 
in neuroblastoma were prevented by the A2AR antagonist ZM241385 (Ferrante et al., 2016). These 428 
findings suggest that A2AR agonists partially improve the NPC1 phenotype, although the mechanisms 429 
leading to the described effects still need to be determined.  430 
Another disease that has been proposed to be affected by cellular cholesterol levels is Alzheimer disease 431 
(AD), which is characterized by the accumulation of amyloid beta (Aβ) protein both internal and 432 
external of neurons (Goate and Hardy, 2012). High levels of LDL favour the internalization of the 433 
peptide precursor of Aβ (AβPP); this process is mediated by interactions with the LDL receptor (Jiang et 434 
al., 2014; Yoon et al., 2007). Thus, it has been proposed that cholesterol augments the risk of developing 435 
sporadic AD (Hui et al., 2012). Interestingly, the Aβ plaques also contain Apo B, the main LDL protein, 436 
and the Apo B levels are positively correlated with the plaque size (Takechi et al., 2010). Therefore, 437 
factors that could prevent the LDL internalization of AβPP may attenuate Aβ accumulation. Recent 438 
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studies have shown that caffeine, an A3R antagonist, could modulate AβPP internalization by regulating 439 
LDL receptor internalization, a phenomenon associated with reduced Aβ levels (Li et al., 2015). In 440 
cultured primary neurons, A3R knockdown, antagonism with caffeine or treatment with the A3R 441 
antagonist MRS1334 inhibits the internalization of LDL and thus AβPP. In the same cell model, the 442 
A3R agonist 2 Cl-IB-MECA increased the neuronal internalization of AβPP (Li et al., 2015). Therefore, 443 
these results suggest that A3R activity could be protective in models of AD at least in part by 444 
suppressing A3R-mediated internalization of AβPP. 445 
Finally, we can speculate that modulating A2A and A3 activity could play a protective role in diseases 446 
that are associated with intracellular cholesterol alterations; therefore, the use of drugs that modulate 447 
ARs function could be considered as new therapeutic options in developing more pharmacological 448 
approaches for the actual treatment of these diseases.  449 
 450 
3.4 Plasma lipid levels and atherosclerosis 451 
Dyslipidaemia is an imbalance of circulating cholesterol levels with high levels of LDL-cholesterol and 452 
low levels of HDL-cholesterol as well increased levels of triglycerides (The National Cholesterol 453 
Education Programme (NCEP) Adult Treatment Panel III (ATP III), 2002). This disorder can occur 454 
under diverse pathological conditions as well as manifest as a physiological condition during pregnancy, 455 
where the maternal cholesterol levels increase by more than 40% (Leiva et al., 2015b; Palinski, 2014). 456 
Dyslipidaemia is the main risk factor associated with the development of atherosclerosis in adults and in 457 
a growing foetus, leading to chronic inflammation and altered oxidative status and subsequent 458 
endothelial dysfunction (Egan et al., 2016; Napoli et al., 1997). For this reason, developing strategies to 459 
control the plasma lipid levels and therefore the atherosclerotic process is essential to controlling this 460 
condition, at least in adults (Figure 3). There are multiple ways by which the lipid levels in the 461 
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circulation are regulated, and adenosine and its receptors have been considered as one of these 462 
regulatory pathways in animal models. Deficiency of these receptors in knockout mice can affect not 463 
only the lipid levels but also the development of atherosclerosis, which will be described in the 464 
following sections (Koupenova et al., 2012a) (Figure 3A).  465 
 466 
A2BR deficiency 467 
A2BR KO mice present impaired glucose and lipid metabolic parameters as well as increased 468 
atherosclerotic lesions. When given normal (Csóka et al., 2014) or high-fat diet (Johnston-Cox et al., 469 
2012) chow, these mice present increased levels of total cholesterol (~50 and 90%, respectively; 470 
primarily as LDL and VLDL) and triglycerides (~60 and 90%, respectively) than wild-type mice (Csóka 471 
et al., 2014). Interestingly, restoring A2BR expression in A2BR KO macrophages via transduction of the 472 
A2BR gene under the control of the CD68 promoter corrected the aberrant changes in the lipid profile 473 
previously described, resulting in values comparable to those of wild-type mice, suggesting that the 474 
absence of A2B in the macrophages triggered dyslipidaemia (Figure 3A) (Johnston-Cox et al., 2014). 475 
Additionally, changes in the lipid profile in these mice were also influenced by increased body weight, 476 
impaired glucose and insulin homeostasis, dysregulated insulin and adipokine levels and adipose tissue 477 
inflammation. All these changes were corrected by the restoration of A2BR in macrophages, suggesting 478 
the relevance of A2BR in macrophages for glucose and lipid homeostasis (Csóka et al., 2014; Johnston-479 
Cox et al., 2012) (Figure 3A).  480 
Interestingly, in a cohort of normal and obese patients, a positive correlation between the expression of 481 
A2BR in the adipose tissue and body mass index as well as waist and hip circumference was observed, 482 
suggesting that as in mice, this adenosine receptor could be relevant in humans (Johnston-Cox et al., 483 
2012). 484 
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Additionally, regarding its role in lipid and glucose homeostasis, A2BR deficiency also leads to 485 
increased atherosclerotic lesions in a mouse model of atherosclerosis, as observed in apolipoprotein E-486 
deficient mice (ApoE KO) fed a high-fat diet (Koupenova et al., 2012b; Plump et al., 1992). Thus, the 487 
A2BR/ApoE double KO mice (A2BR/ApoE dKO) presented ~twofold larger aortic atherosclerotic 488 
lesions compared with ApoE KO mice (Koupenova et al., 2012b). Interestingly, this phenomenon was 489 
associated with higher plasma and hepatic total cholesterol (~80%) and triglyceride (~70%) levels. 490 
Remarkably, bone marrow transplantation showed that A2BR expression in macrophages was not 491 
involved in either the atherosclerosis lesions or lipid changes described in the dKO mice (Koupenova et 492 
al., 2012b). Interestingly, restoring the A2BR levels in the liver by infecting cells with adenovirus 493 
containing an A2BR-expressing vector was associated with reduced levels of plasma and hepatic total 494 
cholesterol and triglycerides (Koupenova et al., 2012b).  495 
The role of A2BR in atherosclerosis and the plasma lipid levels was also evaluated by systemic 496 
administration of the specific agonist BAY 60-6583 in ApoE KO mice, which resulted in reduced 497 
atherosclerotic lesion size and plasma levels of cholesterol and triglycerides (Koupenova et al., 2012b), 498 
confirming that at least hepatic A2BR expression in mice and the activation of this receptor is involved 499 
in controlling the plasma lipid levels and thus the development of atherosclerosis.  500 
Unfortunately, there are no data regarding a possible role of this receptor in controlling the plasma lipid 501 
levels or development of atherosclerosis in humans. Despite this, a study in a cohort of 95 subjects 502 
designated normal or obese with dyslipidaemia showed a correlation between A2BR expression in 503 
visceral adipose tissue and obesity-related dyslipidaemia and dyslipidaemia-induced inflammation 504 
(Wang et al., 2016). These data together with the previously described role of A2BR in reducing 505 
inflammation and foam cell formation strongly suggest an essential role of this receptor as an anti-506 
atherogenic target. However, considering that the effects of adenosine as well agonists and antagonists 507 
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targeting this adenosine receptor are cell and species-dependent, studies in human cells are required for a 508 
better understanding of the role of this receptor in dyslipidaemia and atherosclerosis. 509 
 510 
A2AR deficiency 511 
Along with A2BR, inactivation of A2AR in ApoE KO mice (A2AR/ApoE dKO) was associated with the 512 
inflammatory response and increased plasma levels of cholesterol (Figure 3A); however, its effect in the 513 
development of atherosclerosis in mice was different. A2AR/ApoE dKO mice had elevated levels of 514 
inflammatory markers such as IL-6 and IL-1b as well as alanine aminotransferase. Additionally, the 515 
plasma cholesterol was ~30% higher in the double KO mice than in the ApoE KO, an increase that was 516 
only associated with augmented LDL cholesterol levels (Wang et al., 2009). These changes were also 517 
associated with increased weight (~20%) of the double KO mice compared with the ApoE KO mice. 518 
Unfortunately, the mechanisms associated with increases in the lipids levels in the absence of A2AR are 519 
currently unknown, but it is possible that this activity could be related to hepatic regulation of lipid 520 
modulators similar to that observed in A2BR-deficient mice. 521 
Despite the described pro-atherogenic changes in the double KO mice and the role of A2AR activation 522 
in inducing cholesterol efflux in isolated macrophages, the size of aortic atherosclerotic lesions as well 523 
as the foam cell content in the lesions were surprisingly reduced (~20 and 30%, respectively) in the 524 
double KO mice compared with the ApoE KO mice fed a high-fat diet for three months. Interestingly, 525 
the reduction in the lesion size was greater (~50%) after six months of the same diet, suggesting that the 526 
absence of A2AR protected mice from the development of atherosclerosis, even when receptor 527 
deficiency was associated with increased levels of plasma lipids and pro-inflammatory markers (Wang 528 
et al., 2009). The same study showed that A2AR expression in bone marrow-derived cells was 529 
responsible for the observed changes in the A2AR/ApoE dKO mice, which was different from the 530 
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A2BR/ApoE dKO mice in that the observed alterations in the lipid levels and the development of 531 
atherosclerosis were due to hepatic A2BR expression (Koupenova et al., 2012b).  532 
Regarding the anti-atherogenic mechanisms associated with A2AR deficiency, it was determined that  533 
apoptosis of the foam cells in the atherosclerotic lesions was triggered in the double KO mice. Indeed, 534 
the levels of annexin V and caspase 3 as well as the number of apoptotic cells detected by TUNEL 535 
staining were higher in the double KO mice compared with the ApoE KO mice. The apoptotic process 536 
was associated with increased activation of p38 MAPK as a consequence of the absence of A2AR since 537 
p38 MAPK inhibition prevents foam cell apoptosis (Wang et al., 2009). Therefore, instead of A2AR 538 
deficiency corresponding with increased inflammatory markers and pro-atherogenic dyslipidaemia, the 539 
absence of this receptor appears to be atheroprotective by inducing foam cell apoptosis (Figure 3E).  540 
Remarkably, these results are in opposition to those described in the chapter 3.2.1, where the evidence 541 
supported an anti-atherogenic role of A2AR in isolated macrophages by inhibiting foam cell formation 542 
by stimulating cholesterol efflux. It has been suggested that these controversial findings could be due to 543 
the extreme inability to export cholesterol from macrophages in the double KO mouse (Reiss et al., 544 
2012). Despite this, the difference in the results obtained in studies using isolated cells and in animal 545 
models should be considered. This divergence in the atheroprotective role of A2AR has also been 546 
described for other proteins involved in atherosclerosis development, such as ABCA1. These studies 547 
suggest that, similar to A2AR, the atheroprotective role of ABCA1 may be distinctive in different cell 548 
lines and different mouse strains by an unknown mechanism (Aiello et al., 2002; Joyce et al., 2002, 549 
2006). 550 
Finally, even though it has been suggested that A2AR modulation may be useful for the treatment of 551 
atherosclerosis, there are no data regarding a possible role of A2BR in atherosclerosis in humans. 552 
 553 
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A1R deficiency 554 
As described for A2BR and A2AR, A1R deficiency in mice also modulates the levels of plasma lipids 555 
and thus the development of atherosclerosis (Teng et al., 2014). In mice deficient for ApoE and A1R 556 
(A1R/ApoE dKO) and fed a high-fat diet, A1R deficiency was associated with a 70% increase in the 557 
levels of plasma triglycerides without changes in the total cholesterol levels compared with ApoE KO 558 
mice (Figure 3A). The body weight of the double KO was ~40% higher than that in ApoE KO mice. 559 
Despite this, the size of the atherosclerotic lesions in the aortic arch was reduced by ~50% in the double 560 
KO compared with the ApoE KO fed the same high fat-diet; however, the composition of the lesions 561 
was similar in both mice. Interestingly, the same reduction of atherosclerotic lesions was observed in 562 
ApoE KO mice infused with the A1R antagonist DPCPX for 12 weeks using osmotic pumps (Teng et 563 
al., 2014). The proposed phenomena associated with this anti-atherogenic role of A1R deficiency in 564 
ApoE KO mice include decreased plasma levels of pro-inflammatory molecules (IL-13, IL-5; IL-6, 565 
MCP-1) and down-regulation of proliferating cell nuclear antigen (PCNA, a protein involved in 566 
mitogenic action of A1R) compared with ApoE KO mice. Therefore, it is suggested that A1R could 567 
promote inflammation and smooth muscle proliferation favouring atherosclerosis development (Figure 568 
3D-E) (Teng et al., 2014). Finally, similar to A2BR and A2AR, there are no studies in human tissues or 569 
cells regarding the role of A1R in lipid metabolism or the development of atherosclerosis, a fact that was 570 
also highlighted by Teng et al. (2014). 571 
 572 
A3R deficiency 573 
The role of A3R in lipid metabolism and atherosclerosis development was studied in mice deficient for 574 
ApoE and A3R (A3R/ApoE dKO). This double KO mouse does not present changes in the lipid profile 575 
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or the size or composition of atherosclerotic lesions. Therefore, is suggested that this receptor does not 576 
play a role in these phenomena (Jones et al., 2004). 577 
In summary, as shown in Table 2, all the described evidence strongly suggests that in mice, ARs play a 578 
role in modulating the levels of total cholesterol and the development of atherosclerosis as well as in 579 
protecting the cardiovascular system. A2AR and A1R have a pro-atherogenic functions whereas A2BR 580 
appears to be anti-atherogenic. Remarkably, the mechanisms leading to the control of the plasma lipid 581 
levels by ARs are mainly unknown, and, unfortunately, this is a lack of information about the effects of 582 
this modulation in human tissues or cells. Therefore, the relevance or the possible use of 583 
pharmacological regulation of ARs to control the lipid levels or atherosclerotic lesion size and/or 584 
composition requires future investigation.  585 
 586 
4. The role of plasma lipid levels in the regulation of adenosin receptors function 587 
The previous sections showed that adenosine/ARs participate in the modulation of phenomena related to 588 
the availability of lipids as well in cells in the systemic circulation; thus, these signalling nodes could be 589 
involved in the development of diseases associated with the levels of these lipids. Despite this, it has 590 
been suggested that the circulating lipid levels could also modulate some of the effects of 591 
adenosine/ARs, although the mechanisms involved are not totally understood. 592 
4.1. The role of lipids in adenosine-dependent control of vascular tone 593 
The role of ARs in vascular contraction and relaxation has been studied in several species and vascular 594 
beds. Although A2AR and A2BR are mainly associated with vascular dilation, A1R and A3R are 595 
associated with constriction (Ansari et al., 2007a, 2009; El-Awady et al., 2013; Tabrizchi and Bedi, 596 
2001). Adenosine as well as AR agonists lead to modulation of vascular tone through both endothelium-597 
dependent (mainly mediated by nitric oxide production; Hein et al., 1999; Westermeier et al., 2011) and 598 
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endothelium-independent pathways (adenylyl cyclase/potassium channels; Heaps and Bowles, 2002; 599 
Heaps et al., 2005; Hein et al., 2001; Silver et al., 1984). Both pathways induce smooth muscle 600 
hyperpolarization and relaxation (Heaps and Bowles, 2002; Heaps et al., 2005; Wynne et al., 2009).  601 
Regarding endothelial function, it was determined that an A2BR KO mouse model presented increased 602 
endothelial expression of adhesion molecules such as E-selectin, P-selectin and ICAM-1 in mesenteric 603 
arteries compared with control mice, resulting in the promotion of endothelial dysfunction and a pro-604 
atherogenic profile (Figure 3B) (Yang et al., 2006). In humans, A2AR signalling is required for normal 605 
insulin-stimulated endothelial-dependent relaxation of the umbilical vein, an effect that is blocked in the 606 
presence of the A2AR antagonist ZM-241385 (Guzmán-Gutiérrez et al., 2012; Westermeier et al., 607 
2011). Thus, these data suggest that for a normal endothelial function, A2BR and A2AR are required in 608 
mice and humans, respectively. Interestingly, it has been shown that the ARs involved in these 609 
phenomena depend not only on the species but also on the vascular bed studied (Talukder et al., 2002b).  610 
For example, in the porcine coronary artery, the nonselective adenosine receptor agonist NECA and the 611 
A2AR agonist CGS 21680 induced the relaxation of coronary vessels (Balwierczak et al., 1991). 612 
Infusion of CGS 21680 in rats was also associated with coronary vasodilation, decreased blood pressure 613 
and increases heart rate (Nekooeian and Tabrizchi, 1996). Interestingly, the cerebral arterial bed also 614 
responds to the agonist infusion but with lower sensitivity than the coronary arterial bed, suggesting that 615 
other ARs could be involved (Nekooeian and Tabrizchi, 1996). In perfused hearts isolated from guinea 616 
pigs, CGS 21680 induced an increase of coronary vasodilation, an effect that was impaired by the A2AR 617 
antagonist SCH58261 in a concentration-dependent and competitive manner; this result suggests that 618 
this receptor plays a major role as a mediator of adenosine-dependent coronary vasodilation 619 
(Belardinelli et al., 1998). In hearts isolated from mice, the infusion of adenosine or the adenosine 620 
agonists as 2-chloradenosine (CAD), NECA and CGS 21680 also led to coronary vasodilation, a 621 
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phenomenon inhibited by the selective A2AR antagonist SCH58261, which suggests the involvement of 622 
A2AR in adenosine-mediated dilation of coronary vessels (Talukder et al., 2002b). Interestingly, it has 623 
been suggested that up-regulation of A2AR is a compensatory mechanism to maintain NO-dependent 624 
endothelial function as evaluated by coronary dilation in a mouse model of atherosclerosis (Zhou et al., 625 
2015). 626 
On the other hand, in rat renal arteries, NECA but not CGS 21680 induces relaxation, suggesting that in 627 
this animal model, A2AR is not involved in this activity (Martin and Potts, 1994). Similar effects have 628 
been reported in aortic rings of mice, where adenosine as well as the nonselective agonists NECA and 629 
CAD produced concentration-dependent relaxation, whereas CGS 21680 did not. The relaxation was 630 
inhibited by the addition of an A2BR antagonist, suggesting the involvement of this receptor in the 631 
adenosine-mediated dilation of the mouse aorta (Talukder et al., 2002b).  632 
Regarding A3R, deletion or inhibition of this receptor in a mouse model led to elevated cAMP levels in 633 
the aorta, which was associated with an enhanced A2AR-dependent vasodilator response upon 634 
adenosine administration, suggesting that A3R attenuate the effects of A2AR (Zhao et al., 2000). In the 635 
aorta isolated from mice, it was shown that A3R is associated with endothelium-dependent aortic 636 
contraction through cyclooxygenase-1 (COX-1) modulation (Ansari et al., 2007b) and enhanced ROS 637 
generation possibly by activating Nox2 (El-Awady et al., 2013). A3R has also been shown to inhibit 638 
coronary flow in hearts isolated from mice (Talukder et al., 2002a) and cause vasoconstriction in 639 
hamster arterioles (Shepherd et al., 1996). In summary, there is evidence showing the role of AR 640 
activation/inactivation in the control of vascular tone. However, these effects are dependent on the 641 
vascular bed as well as in the species studied. 642 
Interestingly, has been shown that increased levels of circulating cholesterol and triglycerides (i.e., 643 
dyslipidaemia) can impair adenosine-mediated dilation in coronary vessels. Diabetic dyslipidaemia in 644 
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pigs leads to elevated whole cell potassium current, increased calcium release and subsequent increased 645 
vascular contractility in microvascular coronary vessels (Mokelke et al., 2005). In the same animal 646 
model, the endothelium-independent vasodilatation induced by adenosine in coronary arterioles was 647 
reduced compared with vessels from normocholesterolemic animals. This condition was mainly 648 
associated with impaired pathway coupling of adenylyl cyclase with a voltage-dependent potassium 649 
channel in smooth muscle cells (Heaps et al., 2005, 2008). The activation of this channel leads to 650 
hyperpolarization of the smooth muscle and reduced contractility via reduced calcium entry through 651 
voltage-dependent calcium channels, a mechanism that is potentially impaired by the oxidative stress 652 
associated with hypercholesterolemia (Heaps and Bowles, 2002; Heaps et al., 2005). However, the role 653 
of ARs in increased cholesterol levels was not evaluated (Heaps et al., 2005). 654 
A pathological condition also characterized by dyslipidaemia is metabolic syndrome (MS). This 655 
syndrome is associated with defects in the microvascular function of coronary vessels by alterations in 656 
the receptors and/or ion channels that mediate coronary reactivity to adenosine (Bender et al., 2009; 657 
Knudson et al., 2007). In a pig model of early MS (hypercholesterolaemic and hyperglycaemic pigs), 658 
coronary dilation was determined in vivo by intracoronary infusion of adenosine or determined ex vivo 659 
in coronary arterioles isolated from the same animals, and the activity was similar compared with 660 
vessels from normal pigs (Bender et al., 2009). However, the mechanism that caused arteriole dilation in 661 
control or MS animals was different. In the control pigs, the dilation was only mediated by A2AR, 662 
whereas in vessels from MS animals, both A2AR and A2BR were involved (Bender et al., 2009).  663 
Studies developed in human patients showed that in human coronary arteries, adenosine and its 664 
analogues NECA and L-PIA produced concentration-dependent relaxation, which was inhibited by the 665 
A2R antagonist 8-phenyltheophyline (Ramagopal and Mustafa, 1988). Quantification of myocardial 666 
blood flow in 16 hypercholesterolaemic men with a familiar history of cardiovascular disease using 667 
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positron emission tomography (PET) allowed the detection of an abnormal vasodilator response to 668 
intravenous adenosine infusion (Dayanikli et al., 1994). Similarly, microvascular dysfunction of the 669 
coronary arterioles as evaluated using abnormal transthoracic Doppler echocardiography after 670 
intravenous infusion of the adenosine uptake inhibitor dipyridamole was described in a cohort of 33 671 
patients with MS (i.e., increased levels of LDL and triglycerides but reduced levels of HDL cholesterol) 672 
(Pirat et al., 2008). In a cohort of forty-five MS patients, a reduced coronary flow reserve after infusion 673 
of adenosine was also determined by echocardiography, which was correlated with body mass index, 674 
waist circumference, fasting glucose levels, more sensitive C-reactive protein and the HDL and 675 
triglycerides levels (Tok et al., 2013). Another study with fourteen dyslipidaemic patients showed that 676 
after intravenous adenosine infusion, the myocardial blood flow and endothelial-dependent vasodilation 677 
of coronary vessels was reduced in those subjects as measured by PET (Alexanderson et al., 2010). 678 
Therefore, in coronary vessels, dyslipidaemia could impair adenosine-mediated vasodilation. 679 
However, whether this effect is directly related to dyslipidaemia or whether the involved mechanism 680 
includes ARs was not determined in those studies and is still unknown.  681 
 682 
4.2. Possible role of lipids in adenosine receptor function by changing the membrane microdomain 683 
composition 684 
The previous section described that increased levels of plasma lipids impaired the vascular effects of 685 
adenosine by unknown mechanisms. In this review, we propose that increased lipid levels could 686 
eventually modify the localization and function of AR in the cell membrane. 687 
Interestingly, lipids (especially cholesterol) are key constituent of cell membranes and membrane 688 
microdomains, including lipid rafts and caveolae (i.e., microdomains in the plasma membrane enriched 689 
with the protein caveolin) (Feron and Balligand, 2006). Thus, in conditions such as 690 
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hypercholesterolemia, caveolin is up-regulated, which modifies its localization and the signalling of 691 
proteins located in caveolae (Bist et al., 1997; Blair et al., 1999; Feron et al., 1999). Regarding Ars, it 692 
has been proposed that membrane microdomains such as caveolae play a role in regulating receptors 693 
signalling and participate in the phenomenon of adenosine receptor-desensitization (Lasley, 2011). Thus, 694 
it has been proposed that circulating levels of cholesterol could modulate the activity of ARs.  695 
The plasma membrane/intracellular trafficking of ARs is directly associated with the functional 696 
availability of the receptors at the cell surface and is therefore a process that regulates the capacity of the 697 
receptors’ agonists to produce cellular responses (Mundell and Kelly, 2011). Platelets isolated from 698 
patients with familial hypercholesterolemia (FH) were described as having reduced sensitivity to 699 
adenosine (evaluated as inhibition of platelet aggregation) compared with platelets from either normal 700 
subjects or patients with FH treated with cholestyramine (a resin used to decrease the levels of plasma 701 
cholesterol). Interestingly, NECA binding was not altered between platelets from FH and FH-treated 702 
patients; thus, the difference between both groups of platelets was associated with reduced cAMP 703 
formation in response to NECA. Therefore, it was proposed that in platelets from FH patients, there is a 704 
defect in the coupling of platelet A2AR to adenylyl cyclase (Gasser et al., 1993). We propose that this 705 
defect could be caused by alterations in the adenosine receptor because of changes in the platelet 706 
membrane composition due to the increased availability of cholesterol, which was reported for other 707 
proteins in the caveolae (Cerecedo et al., 2016; Poisson et al., 2009). 708 
Interestingly, all the ARs have a predicted caveolin-interaction sequence in their C-terminal domains 709 
(Mundell and Kelly, 2011). The localization of A1R in the caveolae is well documented; however, 710 
information proposing a direct interaction between caveolin and A2AR, A2BR or A3R is minimal 711 
compared with the data showing its interaction with A1R. 712 
A1R is localized in the caveolae in cardiomyocytes (Lasley et al., 2000), smooth muscle cells (Escriche 713 
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et al., 2003), and epithelial cells (Ginés et al., 2001). In cardiomyocytes, A1R are localized in caveolae 714 
under basal conditions, but after stimulation with agonists such as 2-chloro-N6-cyclopentyladenosine 715 
(CCPA), the receptors translocate out of the caveolae without internalizing (Lasley et al., 2000). 716 
Conversely, in smooth muscle and epithelial cells, upon stimulation with the agonist R-717 
phenylisopropyladenosine ((R)-PIA), A1R is internalized to intracellular compartments by a caveolin-718 
dependent mechanism (Escriche et al., 2003; Ginés et al., 2000). In smooth muscle cells, a direct 719 
interaction between the C-terminal domain of A1R and caveolin-1 has been described (Escriche et al., 720 
2003). After interacting with its ligand, the A1R/ligand complex is endocytosed in a caveolin-dependent 721 
manner, sorted to endosomes and finally recycled back to the cell membrane. Interestingly, in cells 722 
treated with either filipin or methyl-β-cyclodextrin (MβCD) (molecules that modify the cholesterol 723 
content in the cellular membranes to impair caveolae function), the internalization of ligand-bound A1R 724 
was abolished, suggesting that cholesterol levels can modify the normal function of this receptor 725 
(Escriche et al., 2003).  726 
Regarding A2AR, the G proteins coupled to this receptor are localized in caveolae (Wright et al., 2015). 727 
However, compared with A1R, there is no direct evidence of either A2AR localization in lipid rafts or a 728 
direct interaction with caveolin. Despite this, it was described that in rat spinal cord neurons, A2AR co-729 
precipitated with the TrkB receptor (a protein located in lipid rafts) and that A2AR is present in the 730 
cellular fraction corresponding to lipid rafts (Mojsilovic-Petrovic et al., 2006). In rat embryonic cortical 731 
neurons (Assaife-Lopes et al., 2014) and in erythrocytes (Kamata et al., 2008), the effects of the A2AR 732 
agonist CGS 21680 was abolished by lipid raft disruption via MβCD or lidocaine, respectively; this 733 
suggests that A2AR could be localized to this membrane microdomain. Other work suggests that A2A 734 
must be located in lipid rafts to induce G protein-mediated activation of adenylyl cyclase; however, to 735 
activate MAPK signalling pathways, this localization is not required as demonstrated by depletion of 736 
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membrane cholesterol (Charalambous et al., 2008).  737 
The location of A2BR in membrane microdomains enriched in caveolin-1 was reported in the T84 738 
epithelial cell line after stimulation with adenosine; however, a direct interaction of the receptor with 739 
caveolin-1 was not evaluated. Therefore, the localization of A2BR in caveolae was suggested but not 740 
confirmed (Sitaraman et al., 2002). In the HEK293 cell line, the internalization of this receptor was 741 
dependent on arrestin and independent of caveolae (Mundell and Benovic, 2000). Therefore, this 742 
information suggests that A2BR membrane localization and signalling are dependent on the cell type 743 
involved. 744 
Regarding A3R, although there is no direct evidence for its localization in either caveolae or lipid rafts, 745 
fluorescence correlation spectroscopy studies showed that after stimulation with the fluorescent agonist 746 
ABEA-X-BY630, there are at least two different receptor populations in the cell membrane. It was also 747 
proposed that a subpopulation of A3R could be localized in caveolae and that this population could be 748 
involved in A3R-dependent Gi-mediated inhibition of adenylyl cyclase activity (Cordeaux et al., 2008). 749 
Additionally, A3R in CHO-K1 cells was shown to interact with arrestin-2 and arrestin-3 after 750 
stimulation with either NECA or BY630-X-(D)-A-(D)-A-G-ABEA and subsequently internalized. 751 
However, these studies did not evaluate the membrane localization of the receptor (Stoddart et al., 2014, 752 
2015).  753 
Considering that elevated levels of cholesterol can increase the expression of caveolin and alter the 754 
caveolae structure to modulate the activity of proteins located in caveolae (Feron et al., 1999; Greyson et 755 
al., 2013; Mineo and Shaul, 2012; Zhang et al., 2008; Zhang, 2014), we speculate on the possibility that 756 
dyslipidaemia-associated decreases in the effects of adenosine as described in the previous section could 757 
likely be related with alterations of AR function in the membrane microdomains. However, we want to 758 
emphasize that this last section is a proposed theory based in the data from the literature, which can 759 
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alternatively be interpreted by the reader. 760 
 761 
5. Dyslipidaemia in pregnancy: a possible role for adenosine/adenosine receptors 762 
5.1 The role of adenosine in fetoplacental vascular function 763 
Adenosine/ARs signalling are involved in the control of vascular tone as well in mice as in human 764 
tissues (Chapter 4.1). Interestingly, in a pregnancy pathology as gestational diabetes mellitus (GDM), 765 
the expression and function of ARs is altered as a consequence of this maternal metabolic alteration.  766 
GDM is a pregnancy-associated disease that can be comorbid with maternal hyperglycaemia and lead to 767 
foetal hyperglycaemia and hyperinsulinaemia (American Diabetes Association, 2016). Remarkably, 768 
GDM is associated with increased plasma adenosine levels in the umbilical blood (Salomón et al., 2012; 769 
Westermeier et al., 2011), with altered AR expression and signalling and subsequent alterations of 770 
endothelial cell function (Guzmán-Gutiérrez et al., 2012, 2016; Sobrevia et al., 2016). Thus, it has been 771 
described that GDM is associated with increased L-arginine transport and nitric oxide synthesis, both of 772 
which have been attributed to activation of ARs in HUVECs (Guzmán-Gutiérrez et al., 2014; Sobrevia 773 
et al., 2015). Additionally, insulin exposure of HUVECs and human placental microvascular endothelial 774 
cells (hPMECs) from foetuses of pregnant women with GDM reverses these alterations, an effect that is 775 
also dependent on AR activation. Interestingly, activation of ARs is required for this beneficial effect of 776 
insulin, and a crucial role of A2AR activation was recently proposed for the stimulatory effect of this 777 
hormone on hCAT-1-mediated L-arginine transport in HUVECs derived from normal pregnancies 778 
(Guzmán-Gutiérrez et al., 2012). In contrast, a role for A1R is possible to facilitate the beneficial effects 779 
of insulin in reversing the associated activation of the L-arginine/NO signalling pathway in cells from 780 
pregnant women with GDM; this was indicated in comparing these values in cells from pregnant women 781 
with GDM to values detected in cells from normal pregnancies (Guzmán-Gutiérrez et al., 2012, 2014). 782 
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Based on these findings, it has been suggested that a differential role for ARs exists as modulators of the 783 
effects of insulin on the fetoplacental endothelium from normal pregnancies compared with GDM 784 
pregnancies (Guzmán-Gutiérrez et al., 2014).  785 
Additionally to GDM, adenosine/ARs signalling is altered in preeclampsia, a pregnancy pathology also 786 
related with impaired fetoplacental vascular function (reviewed in Salsoso et al, 2017). Therefore, is 787 
suggested that alterations in adenosine/ARs signalling relate with endothelial dysfunction of the 788 
fetoplacental vasculature (Pardo et al., 2013).  789 
 790 
5.2 Dyslipidaemia in pregnancy 791 
GDM and preeclampsia are maternal metabolic alterations associated with fetoplacental endothelia 792 
dysfunction and changes in the function of adenosine/ARs.  Interestingly, there is other maternal 793 
metabolic alteration also related with fetoplacental endothelial dysfunction: maternal supraphysiological 794 
hypercholesterolaemia in pregnancy. However, the role of adenosine/ARs in this condition has been 795 
neglected. 796 
Pregnancy is a physiological state with a complex anatomical and functional interactions between the 797 
mother and foetus. Throughout pregnancy, the mother exhibits progressively increased total cholesterol 798 
concentrations to satisfy the demands of the growing foetus; this maternal dyslipidemia is recognized as 799 
maternal physiological hypercholesterolaemia (MPH) (Basaran et al., 2009; Leiva et al., 2015a). 800 
However, pregnancy-associated hypercholesterolaemia greater than the normal physiological increase 801 
(i.e., over the 75th percentile) is known as maternal supraphysiological hypercholesterolaemia (MSPH) 802 
(Leiva et al., 2013, 2015a; Montes et al., 1984).  803 
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Interestingly, MSPH has been described as well in normal pregnancies as in pregnancies with GDM and 804 
preeclampsia (Barrett et al., 2014; Herrera and Ortega-Senovilla, 2010; Leiva et al., 2015b; Napoli et al., 805 
1997; Marseille-Tremblay et al., 2008; Sánchez-Vera et al., 2007) 806 
In normal pregnancies MSPH is associated with vascular alterations at birth (Leiva et al., 2013, 2015a, 807 
2015b, 2016; Napoli et al., 1997, 1999) and during childhood (Napoli et al., 1999). These vascular 808 
alterations in humans include endothelial dysfunction of the fetoplacental vasculature and early 809 
development of atherosclerosis in the foetal aorta. MSPH is also associated with reduced nitric oxide-810 
dependent dilation of human umbilical vein rings than MPH (Leiva et al., 2013, 2015a). The cellular 811 
mechanism associated with this phenomenon was studied in human umbilical vein endothelial cells 812 
(HUVECs) and included reduced NO synthesis by reduced nitric oxide synthase (NOS); this activity 813 
occurred not with changes in the NOS protein abundance or the NOS dimer/monomer ratio (Leiva et al., 814 
2016) but rather reduced phosphorylation at activating (serine 1177) and inhibitory (threonine 495) 815 
residues on NOS (Leiva et al., 2013) and reduced synthesis of the NOS cofactor tetrahydrobiopterin . 816 
Additionally, MSPH was associated with increased human cationic amino acid transporter (hCAT)-817 
mediated L-arginine transport without changes in the protein abundance of the transporter as well as 818 
increased expression and activity of arginases (Leiva et al., 2013). The early development of foetal 819 
atherosclerosis was described in that the size of the atherosclerotic lesions in the aorta of foetuses from 820 
pregnant women with MSPH were greater compared with that of foetuses from pregnant women with 821 
MPH (Napoli et al., 1997). This phenomenon was also observed during the childhood of children who 822 
gestated in pregnancies of women with MSPH (Napoli et al., 1999). Those lesions were positive for 823 
oxidized LDL, and markers of oxidative stress were detected in the placenta and neonatal blood (Liguori 824 
et al., 2007). Thus, it is feasible that newborns from women with plasma cholesterol levels over the 75th 825 
percentile could potentially have fetoplacental vascular alterations.  826 
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In summary, pregnancy is a condition that relate with maternal dyslipidemia and when the lipid levels 827 
are elevated over a physiological range, fetoplacental vascular function is altered. As previously 828 
described in the chapter 3, adenosine/ARs regulate process related to lipid availability in human cells 829 
and animal models. However, if this regulation also occurs during pregnancy and relates with maternal 830 
dyslipidemia is unknown. Interestingly, adenosine/ARs modulate the fetoplacental vascular function, a 831 
phenomena impaired in pregnancies with maternal dyslipidemia. However, the plasma levels of 832 
adenosine or the signalling of adenosine/ARs under this maternal condition is unknown. Additionally, 833 
and has was discussed in the chapter 4, ARs function could be modulated by dyslipidemia; however, if 834 
this modulation could also occur during pregnancy is unknown. Therefore, we propose a possible 835 
functional link between adenosine/ARs signalling and maternal plasma lipid levels in pregnancy, which 836 
is currently unknown. 837 
 838 
6. Concluding remarks 839 
Adenosine as well as agonists and antagonists of the different AR subtypes play a role in the regulation 840 
of lipid availability in the cell and in the systemic circulation as well in humans and animal models. 841 
Therefore, adenosine/ARs regulate (1) lipolysis leading to a reduction of circulating fatty acid levels 842 
(Figure 2A); (2) atherosclerosis by inhibiting the formation of foam cells via stimulation of cholesterol 843 
efflux and reducing the inflammatory process (Figure 2B and 3); (3) intracellular cholesterol trafficking; 844 
and (4) the plasma levels of total cholesterol and triglycerides (Figure 3). Additionally, increased levels 845 
of lipids impair the effects of adenosine/ARs in the control of vascular tone possibly by altering the 846 
membrane microdomain composition where ARs are localized.  847 
Based in the reviewed evidence, we propose the following: (1) a role of adenosine in regulating lipid 848 
availability; (2) the use of agonists and antagonists of ARs as possible therapeutic agents for classical 849 
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diseases associated with disturbed lipid levels, such as diabetes and atherosclerosis, and diseases 850 
involved in the nervous system, such as Niemann-Pick type C1 and Alzheimer disease; and (3) a 851 
possible role for adenosine/ARs in the phenomenon of dyslipidaemia in pregnancy. 852 
Despite these theories, this review of the available studies highlights the limited information related to 853 
research aimed to determine the role of ARs in human dyslipidaemia/atherosclerosis as well in women 854 
during pregnancy. 855 
 856 
857 
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Table 1. Clinical attempts to use adenosine agonists and antagonists to correct lipid abnormalities 1712 
 1713 
Legend for Table 1 1714 
A1, adenosine receptor subtype 1; FFA, free fatty acids; N, number of subject included in the study. 1715 
 1716 
 1717 
  1718 
Receptor 
involved 
Agonist/ 
antagonist 
Name Objective Type of 
patient 
N Main result Side 
effects 
Reference 
A1 (-) Adenosine To reduce 
plasma 
FFA 
Healthy 11 Unchanged levels 
of plasma FFA  
Dyspnea, 
chest 
pressure 
Swislocki 
et al., 1993 
A1 Agonist ARA To reduce 
plasma 
FFA 
Healthy 26 Reduction of 
plasma FFA with 
receptor 
desensitization 
No 
reported 
Zannikos 
et al., 2001 
A1 Agonist RPR749 To reduce 
plasma 
FFA 
Healthy 48 Reduction of 
plasma FFA  
No Shah et al., 
2004 
A1 Agonist GS-9667 To reduce 
plasma 
FFA 
Obese 59 Reduction of 
plasma FFA 
No Staehr et 
al., 2013 
A1 Agonist GS-9667 To reduce 
plasma 
FFA 
Normal/obese 55/23 Reduction of 
plasma FFA 
No Staehr et 
al., 2013 
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Table 2. Effects of genetic modifications of murine adenosine receptors on plasma lipid levels, the 1719 
development of atherosclerosis and cardiovascular function 1720 
Animal model Effects on 
plasma lipid 
levels 
Effect on 
atherosclerosis 
Efect on cardiovascular 
damage 
Reference 
A1R KO n.d n.d Decreased tolerance to 
ischemia and reperfusion 
Willems and 
Headrick., 2007 
n.d n.d Increased resistance to 
ischemia and reperfusion 
Reichelt et al., 2005 
A1R/ApoE KO Increased Tg Reduced lesion 
size 
 
Teng et al., 2014 
A2AR KO n.d n.d Increased heart rate and blood 
pressure 
Ledent et al., 1997 
n.d n.d Decreased blood flow in 
presence of CGS, NECA and 
Adenine 
Morrison et al., 2002; 
Ponnoth et al., 2009; 
Teng et al., 2008 
n.d n.d Increased blood flow in 
presence of BAY 
Teng et al., 2008 
n.d n.d Decreased aortic relaxation by 
NECA, CGS 
Teng et al., 2008 
n.d n.d Decreased aortic relaxation  Ponnoth et al., 2009 
A2AR/ApoE KO Increased TCh Reduced lesion 
size 
n.d Wang et al., 2009 
A2AR/A2BR KO n.d n.d Decreased coronary flow with 
NECA 
Sanjani et al., 2011 
A2BR KO n.d n.d Decreased coronary flow with 
BAY  
Sanjani et al., 2011 
Increased TCh 
and Tg 
n.d n.d Csóka et al., 2014 
Increased TCh 
and Tg 
n.d n.d Johnston-Cox et al., 
2012 
A2BR/ApoE KO  Increased TCh 
and Tg 
Increased 
atherosclerosis 
n.d Koupenova et al., 
2012b 
A3R KO n.d n.d Increased tolerance to 
ischemia and reperfusion 
Harrison et al., 2002 
n.d n.d Decreased ventricular 
hypertrophy and fibrosis 
Prevention of cardiac 
remodeling 
Lu et al., 2008 
n.d n.d Decreased infart size Guo et al., 2001 
n.d n.d Improved recovery of 
developed pressure in hearts 
after reperfusion 
Cerniway et al., 2001 
A3R/Apo E KO n.d Does not 
influence 
atherosclerosis 
n.d Jones et al., 2004 
A1R transgenic n.d n.d Increased tolerance to 
ischemia and reperfusion 
Matherne et al., 1997 
n.d n.d Decreased heart apoptosis after 
ischemia and reperfusion  
Regan et al., 2003 
n.d n.d Increased tolerance to 
ischemia and reperfusion 
Headrick et al., 1998  
n.d n.d Myocardial protection  Gauthier et al., 1998 
n.d n.d Dilated cardiomyopathy Funakoshi et al., 2006 
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n.d n.d Reduced infarct size  
Preserved cardiac function 
after myocardial infarct 
Yang et al., 2002 
n.d n.d Cardio protective effect by 
preconditioning ischemia 
Dougherty et al., 1998 
A2AR transgenic n.d n.d Increased contractibility Chan et al., 2008 
n.d n.d Increased contractibility Chan et al., 2008 
A3R transgenic  n.d n.d Protection against ischemia 
and reperfusion injury 
Decreased infarct size 
Black et al., 2002 
n.d n.d Dilated cardiomyopathy Black et al., 2002 
n.d n.d Decreased heart rate and 
protection against ischemic 
hearts 
Cross et al., 2002 
n.d n.d Cardio protective effect by the 
preconditioning ischemia 
Dougherty et al., 1998 
 1721 
 1722 
Legend for Table 2 1723 
A1R, A2AR, A2BR, A3R, adenosine receptor subtype 1, 2A, 2B and 3, respectively. ApoE, 1724 
apolipoprotein E. KO, knockout mice. TCh, total cholesterol. Tg, triglycerides. CGS, CGS 21680, an 1725 
A2AR agonist. NECA, 5′-(N-Ethylcarboxamido)adenosine, a nonselective adenosine receptor agonist. 1726 
BAY, BAY60-6583, an A2BR agonist. n.d, not determined. 1727 
  1728 
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Figure 1. Adenosine synthesis, receptors and transporters. Adenosine in derived from ATP and ADP 1729 
released by different sources (see chapter 2.1). Then, ATP is converted to ADP and AMP by 1730 
ectonucleoside triphosphate diphosphohydrolase 1(CD39) followed by conversion to adenosine by ecto-1731 
5-nucleotidase (CD73). Extracellular adenosine can be metabolized to inosine via the ecto-adenosine 1732 
deaminase and/or uptaken via either the equilibrative nucleoside transporters system (ENT) or the 1733 
concentrative nucleoside transporters system (*CNT, a sodium-dependent (Na+) transporter present in 1734 
few type of cells). After adenosine uptake by adenosine transporters, the nucleoside is rapidly 1735 
metabolized to either inosine or AMP by the enzymes adenosine deaminase or adenosine kinase, 1736 
respectively. Intracellularly, adenosine is synthetized either from ATP, ADP, and AMP via the activity 1737 
of cytoplasmic 5’-nucleotidases or from the hydrolysis of S-adenosyl-homocysteine via the action of the 1738 
enzyme S-adenosylhomocysteine hydrolase. Extracellular adenosine activates the adenosine receptors 1739 
A1, A2A, A2B and A3. A1R and A3 are coupled to inhibitory G protein (Gi). A2A and A2B are 1740 
coupled to the stimulatory G protein (Gs). Signalling pathways associated with A1 and A3 include 1741 
adenyl cyclase inhibition, phospholipase C activation (PLC) and PI3K/Akt activation. A2A and A2B 1742 
induce adenyl cyclase activity. All ARs stimulate MAPK. All information regarding these receptors was 1743 
obtained from Burnstock et al., 2011; Eltzschig, 2009; Fredholm et al., 2007. 1744 
 1745 
Figure 2. Adenosine and adenosine receptors participate as modulators of lipolysis, cholesterol 1746 
efflux and inflammation. A) A1R participates in the regulation of lipolysis by inhibiting the different 1747 
lipases involved in this phenomenon in humans and other animal models (Ohisalo el at., 1981; Heseltine 1748 
et al., 1995; Jhoansson et al., 2007). B) A2AR and A2BR inhibit the foam cell formation process by 1749 
regulating cholesterol efflux and inflammation in human and animal cells. Activation of A2AR inhibits 1750 
foam cell formation in macrophages by increasing cAMP production and augmenting ABCA1 and 1751 
CYP27A1 expression and function and subsequently results in decreased cholesterol accumulation. 1752 
Additionally, A2AR inhibit oxidized (oxLDL) uptake. Conversely, A2AR stimulation generates an 1753 
increase in IL-10 and IL-12 release. Additionally, general activation of A2BR in murine macrophages 1754 
results in inhibited TNF-α and IL-1β synthesis as well as increased IL-10 production. Finally, activation 1755 
of A3R could inhibit TNF-α synthesis (Bingham et al., 2010, 2012; Kohan et al., 2001; Kreckler et al., 1756 
2006; Nemeth et al., 2005; Reiss et al., 2004, 2012; Voloshyna et al., 2013a; Xaus et al., 1999).  1757 
 1758 
Figure 3. Adenosine receptors participate in the regulation of lipid levels and the subsequent 1759 
development of atherosclerosis. Increased levels of plasma cholesterol (A) as well as endothelial 1760 
expression of adhesion molecules such as E-selectin, P-selectin and ICAM-1 (B) promote endothelial 1761 
dysfunction (1), an early phenomenon in the development of atherosclerosis (4). Dysfunctional 1762 
endothelial cells favour the attachment of monocytes that express chemokines that produce 1763 
inflammatory signals, which precedes the shift of monocytes to macrophages, which are cells that 1764 
uptake of LDL (C) and promote a pro-inflammatory environment (D) to cause the formation of foam 1765 
cells (2). The accumulation of foam cells and apoptotic foam cells in the intima space leads to the 1766 
development of a fatty streak or early atheromatous lesion (3). Interestingly, most of these phenomena 1767 
could be regulated by adenosine receptors. A2AR, A2BR and A3 could participate in A (modulating 1768 
plasma lipid levels); A2AR in B (decreasing expression of adhesion molecules); A2AR in C (increasing 1769 
cholesterol efflux) and A1R, A2AR and A2BR in D (inhibiting inflammation) (see sections 3.2 and 3.5 1770 
in the text). The information was obtained from Libby et al., 2002; Mestas et al., 2008; Moore and 1771 
Tabas., 2011; Virmani et al., 2002. 1772 
 1773 
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